Publication date: Jul 24, 2024
Recent development of SARS-CoV-2 spike mRNA vaccines to control the pandemic is a breakthrough in the field of vaccine development. mRNA vaccines are generally formulated with lipid nanoparticles (LNPs) which are composed of several lipids with specific ratios; however, they generally lack selective delivery. To develop a selective delivery method for mRNA vaccine formulation, we reported here the synthesis of polymeric nanoparticles (PNPs) composed of a guanidine copolymer containing zwitterionic groups and a dendritic cell (DC)-targeted aryl-trimannoside ligand for encapsulation and selective delivery of an mRNA to dendritic cells. A DC-targeted SARS-CoV-2 spike mRNA-PNP vaccine was shown to elicit a stronger protective immune response in mice compared to the traditional mRNA-LNP vaccine and those without the selective delivery design. It is anticipated that this technology is generally applicable to other mRNA vaccines for DC-targeted delivery with enhanced immune response.
| Concepts | Keywords |
|---|---|
| Lipids | Cov |
| Mrna | Dc |
| Nanoparticle | Delivery |
| Pandemic | Dendritic |
| Vaccine | Elicit |
| Enhanced | |
| Immune | |
| Mrna | |
| Polymeric | |
| Sars | |
| Selective | |
| Synthesis | |
| Targeted | |
| Vaccine | |
| Vaccines |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | cell |
| disease | VO | vaccine |
| disease | VO | LACK |
| drug | DRUGBANK | Guanidine |
| disease | IDO | immune response |